Sandoz and its generic Remodulin (treprostinil) partner Liquidia have welcomed a US court opinion that concluded the firms suffered losses of more than $137m as a result of interference by originator United Therapeutics in the launch of the generic treatment for pulmonary arterial hypertension.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?